R

Rocket Pharmaceuticals

Gene therapies for rare inherited diseases

Vice President - Access, Value Evidence & Pricing

Business OperationsConfirmed live in the last 24 hours
Full-timeCranbury, NJ, USA

About the Job

Requirements

  • A bachelor's degree is required.
  • An advanced degree such as an MBA, PharmD, PhD, MD, or MPH is strongly preferred; significant gene therapy expertise may be considered in lieu of a specific degree requirement.
  • At least 15 years of progressive commercial leadership experience in biopharmaceuticals, with expertise spanning market access, pricing, health economics and outcomes research (HEOR), and patient access in large and emerging company environments.
  • Demonstrated experience leading or influencing value, access, and pricing strategy at product, portfolio, and enterprise levels.
  • Deep expertise in U.S. Buy & Bill and specialty pharmacy reimbursement, commercial and government payer strategy, and access and distribution dynamics of complex cell and gene therapies.
  • Proven track record designing and executing innovative reimbursement models, including outcomes-based contracting, installment payments, managed entry agreements, and risk-sharing arrangements for high-cost therapies.
  • Functional leadership experience in at least two of trade and distribution, patient services, HUB operations, payer marketing, HEOR, and government affairs-adjacent policy engagement.
  • Ability to operate as a peer and strategic partner to executive leaders and senior stakeholders, using strong executive presence, influence, strategic judgment, and communication skills.
  • Demonstrated strategic thinking and comfort operating in novel and ambiguous environments where precedent does not exist and frameworks must be built from scratch.
  • Outstanding written, verbal, and presentation skills to translate complex payer, reimbursement, and evidence concepts for executive, investor, and policy audiences.
  • Willingness to travel domestically and internationally at least 40%.

Responsibilities

  • Serve as Rocket's senior leader for value, pricing, and patient access strategy.
  • Represent the global value, access, and pricing perspective, partnering with Global Product Heads and cross-functional leaders to drive access strategy, evidence planning, launch sequencing, and lifecycle decision-making from early development through commercialization.
  • Provide strategic input into portfolio prioritization, business planning, launch readiness, and external communications by translating payer, health technology assessment (HTA), policy, pricing, reimbursement, diagnostic access, and access dynamics into enterprise-level recommendations.
  • Partner with the Chief Commercialization Officer, Executive Leadership Team, and other senior stakeholders to assess access opportunities, reimbursement risks, pricing considerations, evidence needs, diagnostic access requirements, and the long-term access outlook for Rocket's portfolio.
  • Develop and maintain enterprise-level access readiness dashboards and key performance indicators spanning payer access, reimbursement outcomes, patient access performance, treatment center access barriers, genetic testing coverage and pull-through, pricing assumptions, and pull-through effectiveness.
  • Develop and execute Rocket's integrated global pricing and market access strategy across U.S. commercial and government payers, international markets and access archetypes, and HTA bodies, ensuring sustainable patient access and commercial viability.
  • Anticipate, monitor, and translate emerging international access and policy frameworks, international reference pricing dynamics, diagnostic testing coverage trends, and gene therapy-specific payment models into enterprise portfolio and launch strategy.
  • Lead U.S. market access, pricing, and reimbursement strategy across commercial and government payers, integrated delivery networks (IDNs), launch pricing, gross-to-net assumptions, and innovative access models.
  • Translate U.S. healthcare policy, payer management, diagnostic testing coverage, site-of-care dynamics, and gene therapy payment trends into portfolio strategy, launch planning, and genetic testing access pathways for genetic cardiomyopathies.
  • Partner with the cross-functional launch team to shape U.S. treatment center selection strategy.
  • Lead U.S. treatment center readiness for patient services, HUB operations, genetic testing access resources, and trade, distribution, and channel strategy, ensuring payer, reimbursement, patient support, and operational requirements are embedded into launch readiness and sustained across the product lifecycle.
  • Lead Rocket's HEOR, evidence generation, and value demonstration strategy across the portfolio to support payer decision-making, HTA and reimbursement requirements, genetic testing access, clinical development planning, evidence packages, publications, payer communications, and regulatory and post-approval evidence strategy.
  • Build, lead, and scale a high-performing value, access, and pricing organization with the talent, governance, processes, capabilities, culture, and compliance standards needed to support Rocket's growing portfolio and enterprise objectives.
  • Shape access policy and external engagement by building senior relationships with payers, HTA and reimbursement authorities, policy stakeholders, treatment centers, advocacy organizations, channel partners, and industry coalitions to advance sustainable access to cell and gene therapies.

Desired Qualifications

  • Prior launch experience in gene therapy or innovative treatments is strongly preferred.

About the Company

Rocket Pharmaceuticals

Gene therapies for rare inherited diseases

Rocket Pharmaceuticals develops gene therapies for rare inherited diseases using viral vectors to deliver a working copy of a gene to patient cells. It utilizes adeno-associated virus (AAV) and lentiviral platforms to target disorders of the heart, blood, and other organs, including Danon disease, arrhythmogenic cardiomyopathy, and Fanconi anemia. The company conducts research, clinical development, and manufacturing of investigational therapies, often in collaboration with clinical and research partners, to bring first treatments to diseases with few or no approved options. Its goal is to provide the first gene-therapy treatments for patients with rare inherited diseases that currently have limited or no approved options.

Company size
201-500
Company stage
IPO
Headquarters
Cranbury Township, New Jersey
Founded
2015

Recently Posted Jobs

Explore more opportunities at Rocket Pharmaceuticals

See more jobs